Objective: Low-level HIV-1 replication may occur during antiretroviral therapy (ART) that suppresses plasma HIV-1 RNA to less than 50 copies/ml (suppressive ART). Antiretroviral drugs appear less effective in macrophages and monocytes compared with lymphocytes, both in vitro and as implied in vivo by greater viral evolution observed during suppressive ART. Our objective was to examine sputum, which is rich in macrophages, for evidence of increased HIV-1 replication compared with that in the blood during suppressive ART.
Introduction
Between 20 [1] and 45% [2] of individuals starting antiretroviral therapy (ART) have been reported to fail to achieve sustained suppression of viral replication. Even during seemingly effective ART, low-level viral replication has been evident in the blood of a subset of individuals [3] [4] [5] [6] . Although many individuals demonstrate little or no HIV-1 replication in the peripheral blood mononuclear cells (PBMC) during ART [7, 8] , the slow rate of viral decay during ART suggests replenishment of persisting viral reservoirs [5, 9] . Several observations suggest that blood may not be the optimal tissue in which to assess lowlevel replication. First, plasma HIV-1 sequences during and after ART indicate that PBMC are not the principal source of circulating HIV-1 [7, [10] [11] [12] . Second, mucosalassociated lymphoid tissue is a primary target of HIV-1 [13] , and HIV-1 induces dramatic changes in the mucosalassociated lymphoid tissue [14] [15] [16] that are not reflected in the peripheral blood. Lastly, two studies [16, 17] of gastrointestinal tissue suggest that low-level replication can occur during ART that suppresses plasma HIV-1 RNA below the limit of detection.
HIV-1 replication within specific cells may differ during suppressive ART due to the heterogeneity of intracellular antiretroviral pharmacokinetics [18] . In-vitro studies of macrophages show poor phosphorylation of nucleoside reverse transcriptase inhibitors to the active form [19] and require higher concentrations of protease inhibitors to inhibit viral replication [20] . In addition, increased viral evolution was observed in monocytes compared with lymphocytes separated from cells collected by leukapheresis during suppressive ART [21] . These observations suggest that tissue macrophages may serve as a relative sanctuary during ART without being readily detected in the peripheral blood.
Consistent with this hypothesis, several studies [22] [23] [24] [25] conducted in the pre-ARTera observed that HIV-1 DNA from alveolar macrophages was compartmentalized and more divergent from the most recent common ancestor (MRCA) of infection when compared with PBMCderived virus [22, 23] , suggesting that alveolar macrophages or lymphocytes, or both, in the respiratory tract may be a site of increased viral replication. Most of these specimens were obtained during active pulmonary disease when increased immune activation and viral replication would be expected. High concentrations of HIV-1 in the lung compared with other organs collected during autopsy [24] , and different drug-resistance mutations (assessed by consensus sequencing) in bronchoalveolar lavage compared with blood specimens collected during failing ART [25] , also suggest that the lung may be a site of increased or differential HIV-1 replication. Identifying sites of low-level replication during apparently effective ART may help develop strategies to improve the success of long-term ART [26] . This pilot study examined induced sputa, rich in alveolar macrophages, to gauge the relative amount of HIV-1 replication compared with blood. Sputa and blood were collected from individuals without respiratory symptoms and viral replication evaluated by analyses of single viral genomederived sequences of HIV-1 pol, encoding reverse transcriptase and protease and envelope (env), to predict drug resistance and gauge viral divergence.
Methods

Participants and specimens
A cross-sectional study of HIV-1 DNA from blood and sputa was conducted at Seattle Children's Hospital among children more than 6 years old, with no respiratory symptoms, and receiving ART with plasma HIV-1 RNA less than 50 copies/ml. Informed consent/assent was obtained in accordance with the Institutional Review Board. Alveolar sputa induced by ultrasonic nebulization (Ultra-Neb99; DeVilbiss, Somerset, Pennsylvania, USA) of hypertonic (3%) saline was expectorated after 4 min of inhalation and repeated five times [27] . Sputum was treated with 10% dithiothreitol (Calbiochem, San Diego, California, USA) for 1-2 h, resuspended in phosphate buffered saline (PBS), and quantified (Z1 Coulter Counter; Beckman, Brea, California, USA). Differential cell counts were performed after Wright-Giemsa staining. PBMC (Accuspin tubes; Sigma-Aldrich, St. Louis, Missouri, USA) and sputa cell DNA were extracted using Gentra DNA Purification System (Gentra Systems Inc., Minneapolis, Minnesota, USA).
HIV-1 DNA amplification and quantification
Limiting dilution PCR was performed as previously described [6, 28] . Multiplexed first round PCR of pol and env used three sets of primers (RTA/RT1, PRA/PR2, and ED31/BH2), followed by separate second round reactions with RTB/RT4, PRB/PR4, and ES7/ES8 to amplify the reverse transcriptase and protease regions of pol and the C2-V5 region of env. Alternative primers were occasionally used to optimize amplification, including for the first round: RT2, RTC, Polfo (5 0 -TCAGAGCA-GACCAGAGCCAAC-3 0 ; HXB2 coordinates: 1347-1367), PR5, ED5, ED12, ED3 (5 0 -TTAGGCATCTC-CTATGGCAGGAAGAAGCGG-3 0 ; 5957-5986), and ED14 (5 0 -TCTTGCCTGGAGCTGTTTGATGCCC-CAGAC-3 0 ; 7961-7932); and for the second round: PRC, UHGR, RT3, and Polfi (5 0 -CAACAGCCCCAC-CAGAAGAGA-3 0 ; 2153-2173). Cycling conditions and other primers have been previously published [6] .
Sequencing
Bidirectional sequencing of PCR products was performed as previously described [6] and submitted to 924 AIDS 2009, Vol 23 No 8 GenBank, accession numbers: FJ446721-FJ447017 and FJ447018-FJ447337.
Sequence analysis
Sequences were assembled, edited, aligned, and screened for hypermutation as described [6] . Sequences with ambiguous bases, indicating the possibility of multiple templates, were discarded. Maximum likelihood phylogenetic trees were constructed using the DiverAnalysis web tool (http://indra.mullins.microbiol.washington. edu/cgi-bin/DIVER/diver.cgi). For each individual, reference sequences from the same subtype were used as an outgroup. The inferred sequence at the basal node of each participant's tree was used as an estimate of the MRCA of his/her infection, from which divergence of that participant's extant viral sequences was calculated.
Major drug-resistance mutations in reverse transcriptase were defined as per the International AIDS Society (IAS), USA (http://www.iasusa.org). HIV-1 coreceptor usage was predicted using a X4R5 position-specific scoring matrix (PSSM) [29] . Nonsubtype B sequences were also predicted based on the charge at amino acid positions 11 and 25 [29] .
Statistical analysis
The average viral divergence and frequency of sequences with drug-resistance mutations were calculated for each PBMC and sputum specimen. Because sequences from individuals on suppressive therapy have been shown to regress toward the MRCA [6, 30, 31] , we analyzed average divergence on the assumption that it will be more sensitive to the minority of sequences that had undergone replication. Differences were compared with a Wilcoxon two-sided ranked-sign test, using the mean PBMC and sputum values from each individual participant as a paired set.
Results
Fourteen children, 7-17 years of age, who had been prescribed ART for a median of 6.1 years, were enrolled. Three participants were excluded from analyses; two had sputa with fewer than 2 million cells/specimen; and in the third, PCR failed to amplify HIV-1. The remaining 11 participants included in the analysis were 55% (6/11) women, 64% (7/11) African-American, 18% (2/11) Hispanic, and 9% (1/11) white. Clinical characteristics of these participants and their sputum specimens are shown in Table 1 . Once ART suppressed the plasma HIV-1 RNA to less than 50 copies/ml, low-level viremias were detected on a median of 3% (range 0-17) of determinations, at a median of 97 copies/ml (range 51-308), and none of 283 HIV-1 RNA determinations was greater than 400 copies/ml. Sputa specimens had a median of 16 (range 2-52) Â 10 6 cells, with a median macrophage to lymphocyte ratio of 7.7 (range 3.2 to more than 100), which did not correlate with concomitant PBMC to lymphocyte ratio (Spearman's rank correlation statistic: r ¼ 0.17, P ¼ 0.622). Eighteen to 58 (median 28) single-genome sequences/genes were generated from each participant's specimens with a total of 970 bidirectional sequences analyzed.
The mean divergence of the sputum-derived HIV-1 env sequences from the MRCA in all 11 participants was greater than PBMC-derived sequences (P ¼ 0.004) (Fig. 1a) . The mean divergence of all sputa-derived sequences was 9.9 versus 8.0% for all PBMC-derived sequences. This corresponds to a mean of more than 11 additional nucleotide changes in sputum-derived env sequences compared with PBMC-derived env sequences over the approximately 625-base pair region.
Major protease inhibitor-associated mutations were found in only one participant (J1), whereas mutations associated with resistance to nucleoside analog reverse transcriptase inhibitors (NRTI) were detected in seven of 11, and two of these also had resistance to nonnucleoside reverse transcriptase inhibitors (NNRTI) (Fig. 1b ). All seven of these participants had treatment with mono-NRTI or dual-NRTI prior to HAART. In six of these seven participants, the percentage of sequences with drug-resistance mutations was greater in sputum-derived sequences compared with PBMC-derived sequences, and in one (C1) it was equal (P ¼ 0.05). Across all participants, the mean percentage of sequences with drug-resistant HIV-1 was 52% from sputa versus 36% from PBMC.
Env codons associated with the use of the CXCR4 were found in six of 11 participants. In five of the six, the percentage of X4 sequences was greater in sputa-derived sequences compared with PBMC-derived sequences (P ¼ 0.1), with overall means of 41 versus 31%. The PSSM algorithm is less well validated in nonsubtype B virus. Scoring of basic amino acids at positions 11 and 25 for the two participants with nonsubtype B virus did not change the predicted phenotype of any sequences from I2 (subtype F) but decreased the percentage of predicted X4 phenotypes proportionally in both sputum-derived sequences and PBMC-derived sequences from F1 (subtype D).
Discussion
During suppressive ART, features of HIV-1 sequences indicative of increased viral replication were more common in viruses derived from sputum compared with those from PBMC. Specifically, sputum-derived HIV-1 env had a greater mean divergence from the ancestor of infection, an increase in the frequency of drug-resistance mutations in HIV-1 reverse transcriptase, and a trend to greater X4 genotype. These changes are characteristic of ongoing viral replication in untreated persons [32, 33] . Detection of evolution in two genes ( pol and env) under different selective forces (antiretrovirals and host immunity) strengthens our evidence for increased viral replication in the sputa-derived viral sequences.
A different rate of viral replication in the respiratory tract cells relative to the blood is a straightforward explanation 926 AIDS 2009, Vol 23 No 8 for the observed differences. However, unequal selective pressure and rates of HIV-1 infected cell turnover may also have contributed to the disparity. In this crosssectional study, we cannot determine when or where these differences originated. Longitudinal studies should provide insight into whether viral replication or selection, or both, are ongoing during suppressive ART.
Inflammatory cytokines are associated with increased HIV-1 replication [34] and may have contributed to the differences between viruses we amplified from the sputum and blood, as well as those with pulmonary infections in previous studies [22, 23, 25] . We reason that increased immune activation in cells within the respiratory tract mucosa and associated lymphoid tissue, even in the absence of respiratory symptoms, could enhance viral replication or the proliferation of infected cells, or both, compared with the blood.
Given that macrophages were more prevalent than lymphocytes in all sputa, and that the HIV-1 DNA loads we measured in sputa were similar to published levels in purified alveolar macrophages [23, 35] , it is tempting to speculate that the observed differences are due to HIV-1 from alveolar macrophages. However, recently published data suggest that the bulk of HIV-1 DNA in bronchoalveolar lavage specimens comes from lymphocytes [36, 37] . This suggests that the differences in HIV-1 sequences we derived from sputum versus blood may be due to sampling a different population of cells associated with the respiratory tract mucosa.
Conclusion
In summary, increased viral divergence and drug resistance in sequences derived from sputa compared with the blood indicates relatively greater HIV-1 replication in the respiratory tract. Longitudinal characterization of viral evolution by sputa cell-type should determine whether specific respiratory tract cells provide a sanctuary from ARTand allow low-level viral replication during ART that appears suppressive by blood tests.
